市場調查報告書
商品編碼
1308490
腫瘤生物學名藥市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會及預測Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球腫瘤生物學名藥市場規模達到38億美元。展望未來,IMARC Group預計到2028年,該市場規模將達到147億美元,2023-2028年期間的年複合成長率(CAGR)為21.6%。
癌症是一種生活方式疾病,由於細胞的異常生長而發生,並可能導致腫瘤的形成。目前,大多數有效的癌症治療方法都是基於生物藥物,也稱為生物製劑,包括靶向治療和免疫治療。這些藥物是利用細菌、酵母、動植物細胞等活體生產的,需要複雜的生產流程和較長的研發時間。因此,這些藥物的成本相對較高,增加了癌症治療的費用。為了降低治療費用,人們對開發品牌腫瘤生物製劑的生物學名藥越來越感興趣。這些生物學名藥在有效性和安全性方面與參比生物製劑高度相似,由於成本較低,可幫助大幅降低癌症治療費用。
多年來,老年人口數量的增加和環境惡化使全球癌症發病率上升。這些因素以及癌症治療成本的不斷攀升加重了全球醫療系統的負擔。因此,許多國家的管理機構正在推動生物學名藥的應用,以此作為一項成本控制措施。例如,美國食品和藥物管理局(USFDA)為醫生和患者編制了資訊資料,向他們宣傳生物學名藥。除此之外,可負擔得起的藥物的可用性也與更早和更廣泛地使用治療以及改善患者就醫相關。除此之外,腫瘤生物學名藥還能增加行業競爭,因此有可能進一步降低生物藥的價格。其他一些促進市場成長的因素包括品牌生物製劑專利到期的臨近以及生物學名藥生產商研發活動的增加。
The global oncology biosimilars market size reached US$ 3.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 14.7 Billion by 2028, exhibiting a growth rate (CAGR) of 21.6% during 2023-2028.
Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.
Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on drug type, cancer type and distribution channel.
Monoclonal Antibody
Immunomodulators
G-CSF
Hematopoietic Agents
Others
Lung Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Kidney Cancer
Stomach Cancer
Brain Cancer
Others
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others
Europe
Asia Pacific
North America
Middle East and Africa
Latin America
The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.